FDA Approves Human Testing on Castle Chemical’s

Groundbreaking New Drug ZestaMeloxBachoEchycim

BATH, Ohio, September 17, 2019/PRNewswire

Castle Chemicals has been given the green light to proceed with human testing on their groundbreaking new drug.  Clinical tests have shown that the drug ZestaMeloxBachoEchycim is effective in eliminating the helio-ophthalmic outburst syndrome with spontaneous dentohydroplosion in lab animals.  As such, the FDA is approving human testing.  Testing will commence immediately.

The announcement is somewhat unexpected, due to the fact that the Piedmont AZ’s facility had failed to successfully contain a test specimen of an upper-atmosphere microorganism.  The organism somehow was released into the atmosphere, causing nearly instantaneous disseminated intravascular coagulation in the tri-state area.

Michael Ehrman, President and CEO at Castle Chemicals is on record saying “We implemented stringent infection prevention protocols since the Piedmont’s strain, ensuring that our methods will give our patients and staff peace of mind that our drug is safe and continually improving.  The drug works at the genetic level, so we consulted with Henry Wu of InGen to add additional safeguards to avoid incorrect DNA sequencing.”

The project will be overseen by US Army virologist Lieutenant Colonel Robert Neville, with assistance from Will Rodman, formerly of Gen-Sys.

Copyright © Trail of Terror. All rights reserved.

Type your paragraph here.